Details of the Target
General Information of Target
Probe(s) Labeling This Target
ABPP Probe
| Probe name | Structure | Binding Site(Ratio) | Interaction ID | Ref | |
|---|---|---|---|---|---|
|
A-EBA Probe Info |
![]() |
2.79 | LDD0215 | [1] | |
|
YN-1 Probe Info |
![]() |
100.00 | LDD0444 | [2] | |
|
STPyne Probe Info |
![]() |
K17(7.24); K41(4.74); K57(3.64) | LDD0277 | [3] | |
|
OPA-S-S-alkyne Probe Info |
![]() |
K17(3.74) | LDD3494 | [4] | |
|
5E-2FA Probe Info |
![]() |
N.A. | LDD2235 | [5] | |
|
m-APA Probe Info |
![]() |
N.A. | LDD2234 | [5] | |
|
2PCA Probe Info |
![]() |
K17(0.00); R32(0.00); K41(0.00) | LDD0034 | [6] | |
|
Acrolein Probe Info |
![]() |
H51(0.00); H21(0.00) | LDD0217 | [7] | |
|
TER-AC Probe Info |
![]() |
N.A. | LDD0426 | [8] | |
|
HHS-482 Probe Info |
![]() |
Y43(8.25) | LDD2239 | [9] | |
PAL-AfBPP Probe
| Probe name | Structure | Binding Site(Ratio) | Interaction ID | Ref | |
|---|---|---|---|---|---|
|
FFF probe14 Probe Info |
![]() |
20.00 | LDD0477 | [10] | |
|
FFF probe4 Probe Info |
![]() |
20.00 | LDD0466 | [10] | |
|
VE-P Probe Info |
![]() |
N.A. | LDD0396 | [11] | |
|
Photocelecoxib Probe Info |
![]() |
A22(0.00); E24(0.00); A29(0.00); E31(0.00) | LDD0019 | [12] | |
Competitor(s) Related to This Target
The Interaction Atlas With This Target
The Protein(s) Related To This Target
Enzyme
| Protein name | Family | Uniprot ID | |||
|---|---|---|---|---|---|
| NADH-cytochrome b5 reductase 3 (CYB5R3) | Flavoprotein pyridine nucleotide cytochrome reductase family | P00387 | |||
| Nitric oxide synthase 3 (NOS3) | NOS family | P29474 | |||
Transporter and channel
| Protein name | Family | Uniprot ID | |||
|---|---|---|---|---|---|
| Hemoglobin subunit beta (HBB) | Globin family | P68871 | |||
Other
The Drug(s) Related To This Target
Approved
Phase 3
| Drug Name | Drug Type | External ID | |||
|---|---|---|---|---|---|
| Efaproxyn | Small molecular drug | D03HVV | |||
| Hemoglobin Raffimer | . | D0H4CB | |||
| Polyheme | . | D00IWL | |||
Phase 2
Investigative
Discontinued
References














